MIBELAS 24 FE

Post-LOE

norethindrone acetate, ethinyl estradiol and ferrous fumarate

Lupin Ltd.

ANDAORALTABLET

Approved

May 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

MIBELAS 24 FE (norethindrone acetate, ethinyl estradiol and ferrous fumarate) by Lupin Ltd. is ovulation. First approved in 2016.

Drug data last refreshed 6h ago

$0.0BPart D

Mechanism of Action

ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Lupin Ltd.

See all Lupin Ltd. products →

Worked on MIBELAS 24 FE at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.